Western blot analysis was performed as previously described (23). Antibodies against p-RbSer780, Rb, cyclin D1, CDK4 and CDK6, c-Myc, p-AKTSer473, AKT, p-mTORSer2448, mTOR, p-p70S6KThr389, p70S6K, p-AMPKα1Thr172, p-ERK1/2Thr202/Tyr204, ERK1/2, p-PKM2Tyr105, PKM2 were from Cell Signaling Technology, Incorporated (Danvers, MA); anti-p-CDK6Tyr24 and anti-MCT4 were from Santa Cruz Biotechnology, Incorporated (Dallas, TX). Antibodies against CDKN2A/p16INK4a, AMPKα1, GLUT-1 were from Abcam (Cambridge, UK). Antibodies against HIF-1α and HIF-2α were from BD Biosciences (Franklin Lakes, NJ) and Novus Biologicals, LLC (Centennial, CO), respectively. Anti-β-actin (clone B11V08) was from BioVision (Milpitas, CA). Horseradish peroxidase-conjugated secondary antibodies and the chemiluminescence system were from Millipore (Millipore, MA). Reagents for electrophoresis and blotting analysis were from BIO-RAD Laboratories (Hercules, CA). For GLUT-1 detection, cells were lysed in GLUT-1 lysis buffer (1 % Triton X-100, 0.1% SDS, protease inhibitors) for 1 h on ice, and precleared by centrifugation for 10 min at 4°C. Protein extracts were denatured in sample buffer for 30 min before electrophoresis (24). The chemiluminescent signal was acquired by C-DiGit R Blot Scanner and the bands were quantified by Image Studio™Software, LI-COR Biotechnology (Lincoln, NE).
Do you have any questions about this protocol?
Post your question to gather feedback from the community. We will also invite the authors of this article to respond.